SCHEMBL23736343

SCHEMBL23736343

O=c1ccc(-c2ccc(OC(F)F)cc2)nn1Cc1nc(-c2ccccc2)ns1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ AKR1B1 P15121 1/20 0.44
▸ TP53 P04637 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ PPARD Q03181 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ HDAC1 Q13547 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23528573 0.81 MEN1 (0.46) MEN1KMT2ATP53POLBHSD17B10
SCHEMBL23528318 0.80 KMT2A (0.47) MEN1KMT2AAKR1B1TP53POLB
SCHEMBL23528317 0.80 MEN1 (0.46) MEN1KMT2AAKR1B1TP53POLB
SCHEMBL23528455 0.78 MEN1 (0.46) MEN1KMT2ATP53POLBHSD17B10
SCHEMBL23528522 0.76 MET (0.45) MEN1KMT2ATP53HSD17B10KDM4E
SCHEMBL23528583 0.75 MEN1 (0.46) MEN1KMT2ATP53POLBHSD17B10
SCHEMBL23528279 0.75 GRIN2B (0.45) MEN1KMT2ATP53HSD17B10KDM4E
SCHEMBL23528728 0.75 MEN1 (0.46) MEN1KMT2AAKR1B1TP53POLB
SCHEMBL26999085 0.74 GRIN1 (0.47) MEN1KMT2ATP53HSD17B10KDM4E
SCHEMBL23528301 0.73 MEN1 (0.39) MEN1KMT2ATP53HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012395-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885AKR1B1 1542/4885
US-11873290-B2 — IL6, MUSK, IL6ST MEN1 4771/4885KMT2A 4022/4885AKR1B1 1399/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885AKR1B1 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback